BioSpace News Archive

Increasing adoption of precision medicine solutions in various emerging economies around the world as well as rapid adoption of artificial intelligence and cloud based computing solutions in field of precision medicine are creating exciting new opportunities in the global precision medicine software market.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the VENTANA PD-L1 (SP263) Assay is available in countries accepting the CE mark as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients eligible for treatment with Libtayo® (cemiplimab), a PD-1 inhibitor therapy developed by Regeneron.

Privo Technologies, Inc. (“Privo”, “the Company”) announced today that it has been awarded a $2M Direct-to-Phase II SBIR Contract from the National Cancer Institute (NCI), part of the National Institutes of Health.

Atreca, Inc. announced that it will present at the following upcoming investor conferences.

MY01 Inc. today announced that interim data from an ongoing, prospective multi-center study was presented at the Clinical Orthopedic Society (COS) Annual Meeting in San Antonio, Texas.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to nine new employees.

Statera Biopharma, Inc. announced - as disclosed via the Company’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on Friday, September 9, 2022 - that on September 1, 2022, the Company was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that its common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), and Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo”), today announced that additional data from Mereo’s Phase 2b ASTEROID study related to setrusumab (UX143) and information on the Phase 2/3 Orbit study will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting.

According to Transparency Market Research’s latest report on the global oncolytic virus immunotherapy market for the historical period 2018–2019 and forecast period 2020–20230, promising pipeline is projected to drive the global oncolytic virus immunotherapy market.

Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized COMIRNATY®, the companies’ COVID-19 vaccine, as a three 3-μg primary series for children 6 months to less than 5 years of age.